Isoliquiritin is a flavonoid glycoside compound from licorice possessing a broad spectrum of pharmacological activities including antioxidant, anti-inflammatory, and anti-depression activities. It was shown that isoliquiritin has a cytoprotective effect on corticosterone-induced neurotoxicity in PC12 cells, which may be related to its antioxidant action, inhibition of [Ca2+]i overload, and inhibition of the mitochondrial apoptotic pathway. In addition, it was found that isoliquiritin inhibited the p53-dependent pathway and showed crosstalk between Akt activities. Thus isoliquiritin may be an alternative agent for the treatment of lung cancer.

WIN 55212-2 is the synthetic cannabimimetic compound. It is a potent aminoalkylindole cannabinoid receptor agonist. WIN 55,212-2 increases expression of anti-oxidant Cu/Zn SOD and is able to prevent inflammation induced by Aβ1-42 in cultured astrocytes. It exerts neuroprotective and anti-inflammatory actions against Aβ damage through both CB₁ and CB₂ receptors. WIN 55212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. In the clinical trial, it was revealed that WIN 55212-2, applied topically, decreases the intraocular pressure of human glaucoma resistant to conventional therapies within the first 30 min.